UNSPSC 51341505: Fosamprenavir calcium

This classification denotes a protease inhibitor C25H34N3O9PS.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ID1GU2627N, chemically known as (3s)-tetrahydro-3-furyl ((.alpha.s)-.alpha.-((1r)-1-hydroxy-2-(n1-isobutylsulfanilamido)ethyl)phenethyl)carbamate, calcium phosphate (ester) (1:1), but more generally known as fosamprenavir calcium, which bears US NIH Compound Identifier 131535. European Medicines Agency schedules Fosamprenavir calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20055.

UNSPSC 51341505 Fosamprenavir calcium is a Commodity code that nominally names a specific antiretroviral pharmaceutical product, yet the recent state and local procurement activity under this code does not align with that scope. The two most recent opportunities tagged to the code involve naloxone (an opioid-overdose reversal medication) and unrelated antimicrobial agents (doxycycline and ciprofloxacin), not fosamprenavir or HIV-treatment pharmaceuticals. The tagging mismatch suggests either a data-entry error in the state and local systems or a misclassification by procurement offices. Issuing bodies using this code include state health departments and county governments procuring pharmaceuticals through piggyback awards and competitive bids. The Illinois Department of Public Health awarded a pharmaceutical warehouse contract to Chartwell Rx LLC in August 2026 for antimicrobial agents valued at $2,999,999.11 over the contract lifecycle; Seminole County, Florida issued an IFB in June 2026 for naloxone and drug-deactivation systems, seeking 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries.

Recent activity appears concentrated in Florida and Illinois, though the mismatch between the code's stated commodity and what is actually being procured suggests this code may not be reliably used across jurisdictions for fosamprenavir or related HIV pharmaceuticals. The Illinois award was completed under a piggyback arrangement through the MMCAP Infuse consortium, indicating that state and local buyers may be leveraging cooperative purchasing vehicles for pharmaceutical procurement. The Seminole County procurement required vendors to meet E-Verify, drug-free workplace, and insurance requirements, with potential FEMA funding and federal compliance obligations. Neither opportunity shows explicit small-business, minority-business, women-business, or veteran-business set-asides. The code shows minimal recent activity overall, and the opportunities tagged to it are not clearly related to the pharmaceutical product named in the UNSPSC description.